Live Birth Rate After First Embryo Transfer With or Without Glucocorticoid Sensitivity Testing (NCT07449494) | Clinical Trial Compass
CompletedNot Applicable
Live Birth Rate After First Embryo Transfer With or Without Glucocorticoid Sensitivity Testing
France148 participantsStarted 2020-09-01
Plain-language summary
This retrospective single-center observational cohort study evaluates live birth rates after the first embryo transfer following immune assessment in infertile women with documented uterine immune overactivation.
In routine clinical practice, glucocorticoids represent first-line therapy for immune overactivation. Some patients underwent glucocorticoid sensitivity testing prior to embryo transfer based solely on standard clinical practice and patient preference. In cases of demonstrated glucocorticoid resistance, alternative therapeutic strategies were implemented according to usual care.
The study analyzes clinical data collected between September 2020 and November 2025 to assess the association between prior glucocorticoid sensitivity testing and live birth rate after the first fresh or frozen blastocyst transfer performed following immune evaluation.
No treatment allocation was determined by a study protocol.
Who can participate
Age range
40 Years
Sex
FEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Infertile patients undergoing IVF with planned fresh or frozen embryo transfer
* Age ≤ 40 years at the time of the transfer
* Documented uterine immune over-activation
* Treatment with glucocorticoids in routine clinical practice, with or without prior glucocorticoid sensitivity testing
* Fresh or frozen blastocyst transfer performed within 9 months following immune assessment at Hôpital des Bluets
Exclusion Criteria:
* • Age \> 40 years
* No available uterine immune profile
* Normal immune profile or immune underactivation
* Management exclusively with alternative therapeutic strategies (e.g., low molecular weight heparin \[LMWH\], intralipid therapy) or combination therapies (e.g., LMWH + glucocorticoids or intralipid + glucocorticoids)
* Embryo transfer performed more than 9 months after immune assessment
* Cleavage-stage embryo transfer
* Embryo transfer performed in another center
* Oocyte donation IVF cycles
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Live Birth Rate After First Embryo Transfer
Timeframe: From first embryo transfer to delivery (up to approximately 9 months)